Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Servier Russia
Treatment with the studied drug:
* Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg
* Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg
* Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg This is non-interventional study that is observational by its nature. Therefore there will be no any assignments of subjects to a particular therapeutic strategies defined by this protocol. Decision to treat a patient with SPC of amlodipine/ atorvastatin/ perindopril should be at the descretion of a treating investigator and made in accordance to local standards and protocols.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Obtained signed informed consent from the patient
Patients of 18 years and older and younger than 80 years.
Start of the treatment with SPC of amlodipine/atorvastatin/perindopril within 1 month from the Index date in accordance with the indication in Russian SmPC.
Presence of the parameters of interest\* in the medical records dated with the nearest to the start of SPC amlodipine/atorvastatin/perindopril treatment date.
* Parameters of interest include measured at rest office BP and LDL-C.
You may not be if
Subjects who are unwilling or unable to provide a signed informed consent form;
Any contraindication to the treatment with the SPC of amlodipine/atorvastatin/perindopril according to its' approved instruction for medical use in the Russian Federation;
Concomitant use of any other ACE inhibitors, CCBs, ARBs and statins.
Supposed low treatment adherence to the assigned SPC and the risk for poor collaboration between the patient and the investigator during the study;
Any severe, decompensated or unstable somatic diseases or states that according to investigator discretion are life-threatening or worsen the prognosis for the patient: myocardial infarction in the past 3 months, unstable angina, current decompensation of diabetes mellitus, autoimmune or oncological diseases, severe cardiac arrhythmia, gastrointestinal disorders affecting absorbtion, severe hepatic diseases, pancreatic diseases, severe allergic reactions, connective tissue diseases etc;
Secondary arterial hypertension;
Alcohol or any drug abuse;
Surgical intervention on heart or coronary vessels (i.e., heart valve(s) replacement, stent implantation or CABG), or any non-cardiological serious surgical intervention that are planned within next 3 months and may require withdrawal or changes in current therapy;
Glomerular filtration rate less than 60 ml/min/1,72m2;
Participating in any other clinical trial currently or during 30 days period before informed consent was signed.
Clareo Health | Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)
